NT-proBNP is one of the most valuable biomarkers for heart failure (HF). Its clinical value includes the diagnosis of HF, assessment of disease severity and prognosis, monitoring of cardiac function, and supporting the evaluation of acute coronary syndrome (ACS).
The current landscape of NT-proBNP measurements includes two different approaches. One option is an assay that measures a subfraction of NT-proBNP, specifically the non-glycosylated form in the 42-46 region. Hytest in-house assay, utilizing the new generation antibodies specific to epitopes 27–31 (Cat. # 4NT1cc NT13) and 43–46 (Cat. # 4NT1cc NT45) provides a solution for option one. It demonstrated a good correlation with the Roche proBNP II assay on lateral flow platform (detection range: 40 – 40000 pg/mL, r> 0.99).
However, the first option is sensitive to glycosylation of NT-proBNP, which can lead to underestimated result. To address this issue, Hytest suggests using terminal epitopes to develop total NT- proBNP assay, which is insensitive to glycosylation and can detect the real NT-proBNP. Our representative pair Cat. # 4NT1cc 15C4cc (capture)- Cat. # 4NT1cc 18H5cc (detection) for measuring total NT-proBNP shows the same diagnosis value of HF and the advantages on prognosis value on HF compared to commercially available assays.
Moreover, Hytest recombinant NT-proBNP antigen, Cat. # 8NT2, is promising for NT-proBNP standardization.
For more information. Please check our TechNotes and #4NT1cc product page